A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis

Trial Profile

A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Dec 2017

At a glance

  • Drugs Ixekizumab (Primary) ; Adalimumab
  • Indications Psoriatic arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms SPIRIT-P1
  • Sponsors Eli Lilly
  • Most Recent Events

    • 01 Dec 2017 According to an Eli Lilly media release, FDA has approved Taltz (ixekizumab) injection 80 mg/mL for the treatment of adults with active psoriatic arthritis (PsA). The efficacy and safety of Taltz was determined from findings from two Phase 3 studies- SPIRIT-P1 and SPIRIT-P2.
    • 08 Nov 2017 Results (n=679) from SPIRIT-P1 and SPIRIT-P2 studies assessing the contribution of joint and skin improvements in the health-related quality of life (HRQoL) patients with active patients with active Psoriatic Arthritis, presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
    • 08 Nov 2017 Results of association of achievment of minimal disease activity and improvement in health-related quality of life data from two studies (SPIRIT-P1 and SPIRIT-P2) presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top